Search clinical trials for: N-803 Carboplatin Nab-paclitaxel Pembrolizumab

Total 378 results

iOMEDICO AG
Bristol-Myers Squibb

Completed

Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC (NEPTUN)

Carcinoma, Non-Small-Cell Lung

Germany
Barwon Health
Australasian Gastro-Intestinal Trials Group; Deakin University; Specialised Therapeutics...

Unknown

A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas (NABNEC)

Gastrointestinal Neuroendocrine Carcinomas

Australia
National Cancer Institute (NCI)

Recruiting

Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Gastroesophageal Junction (GEJ) Cancers | Advanced HNSCC

United States
Xiaohua Wu

Recruiting

Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery

Cervical Cancer | Neoadjuvant Immunotherapy | Fertility-sparing Surgery

China
Celgene

Completed

Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2 (AboundPS2)

Carcinoma, Non-Small-Cell Lung

United States
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
John L. Villano, MD, PhD

Active, not recruiting

Pembro+Chemo in Brain Mets

Cancer | Lung Cancer | Lung Cancer Metastatic | Brain Cancer

United States
MedImmune LLC

Active, not recruiting

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Selected Advanced Solid Tumors

Italy, Spain, United States, France, Korea, Republic of, Taiwan, Australia, Netherlands, Portugal
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer

Non-small Cell Lung Cancer
Beijing Tongren Hospital

Recruiting

Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy | Pembrolizumab

China
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
Beijing Friendship Hospital

Recruiting

Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma

Esophageal Carcinoma | Neoadjuvant Immunotherapy

China
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer

United States, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Japan, Turkey, Brazil, Taiwan, Thailand, Canada, Argentina, India, France, Singapore, Mexico, Germany, Philippines, Poland, South Africa
Corcept Therapeutics
Gynecologic Oncology Group

Active, not recruiting

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Neoplasm

United States, Argentina, Australia, Belgium, Brazil, Canada, France, Hungary, Israel, Italy, Korea, Republic of, Poland, Spain, United Kingdom
Centre hospitalier de l'Université de Montréal...
Celgene; Jewish General Hospital; Centre de Recherche du Centre Hospitalier de... and other collaborators

Completed

Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001)

Lung Cancer

Canada
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer

Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
NextCure, Inc.

Withdrawn

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

Non-Small Cell Lung Cancer | Advanced or Metastatic Solid Tumors
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel

Non Small Cell Lung Cancer

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer

Tongue Cancer | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Squamous Cell... and other conditions

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

Neoplasms

Italy, United States, Australia, Canada, Chile, Israel, Korea, Republic of, Spain
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Active, not recruiting

Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer

Breast Cancer

United States
Celgene

Completed

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States, Canada
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Esophageal Small Cell Carcinoma

China
Guangdong Provincial People's Hospital

Recruiting

Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

Head and Neck Squamous Cell Carcinoma

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Fondazione Michelangelo

Completed

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1 (NeoTRIPaPDL1)

Invasive Ductal Breast Carcinoma

Spain, Ireland, Italy, Taiwan, Germany, Austria, Russian Federation
Celgene

Completed

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

Squamous Cell Carcinoma, Non-Small-Cell Lung

United States, Spain, Germany, Italy, United Kingdom
University of Colorado, Denver
Cancer League of Colorado

Withdrawn

Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC

Metastatic Breast Cancer | Triple Negative Breast Cancer | Locally Advanced Breast Cancer | Unresectable Breast Carcinoma | PD-L1 Gene Mutation

United States
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Cancer

China
Chinese Society of Lung Cancer

Completed

Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung (C-TONG1002)

Carcinoma, Non-Small-Cell Lung

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

Triple Negative Breast Cancer (TNBC)
Guangdong Association of Clinical Trials

Not yet recruiting

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Non-Small-Cell Lung Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

Carcinoma, Squamous Cell, Non-small-cell Lung

Poland, Korea, Republic of, United States, Argentina, Australia, Austria, Brazil, Canada, France, Germany, Japan, Mexico, New Zealand, Romania, Russian Federation, Spain, Taiwan, Turkey, Ukraine, United Kingdom
University of Utah

Recruiting

Tumor Treating Fields for Locally Advanced NSCLC (NOVOCURE)

Non Small Cell Lung Cancer

United States
BeiGene

Completed

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Non-Small Cell Lung Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shenzhen Sixth People's Hospital; Zhongshan People's Hospital, Guangdong, China

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Head and Neck Squamous Cell Carcinomas

China
Ruijin Hospital

Recruiting

Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer (NeoPATH)

Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer

China
Adrienne G. Waks
Merck Sharp & Dohme LLC

Active, not recruiting

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

Breast Cancer

United States
Lund University Hospital
Danish Breast Cancer Cooperative Group; Swedish Breast Cancer Group; Finnish... and other collaborators

Recruiting

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

Breast Cancer | Triple Negative Breast Neoplasms

Denmark, Sweden
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

Non-small Cell Lung Cancer

United States, Korea, Republic of, China, Japan, Taiwan, Brazil, Argentina, Chile, Netherlands, Hong Kong, Spain, Italy, France, United Kingdom, Canada, Germany, Israel, Mexico, Portugal, Turkey, Austria, Belgium, Singapore
Genmab
BioNTech SE

Recruiting

GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors

Melanoma | Malignant Solid Tumor | Non Small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Colorectal Cancer (CRC)

United States, Taiwan, Spain, Israel, Korea, Republic of, France, Italy, Denmark, Germany, United Kingdom, Georgia, Moldova, Republic of
GU Research Network, LLC

Withdrawn

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma

China
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Metastatic Non-small Cell Lung Cancer

Japan
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Breast Cancer | HER2-positive Breast Cancer

China
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.; Celgene Corporation

Completed

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
AbbVie

Active, not recruiting

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Cancer | Advanced Solid Tumors | Metastatic Solid Tumors | Triple-Negative Breast Cancer (TNBC) | Non-small-cell-lung-cancer (NSCLC)

United States, Australia, France, Israel, Spain, Taiwan
Fondazione del Piemonte per l'Oncologia

Completed

A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP) (AGNOSTOS)

Unknown Primary Tumors

Italy

Search clinical trials for: N-803 Carboplatin Nab-paclitaxel Pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations